This is a preview of subscription content, log in via an institution to check access.
Notes
classified as having a Migraine Disability Assessment [MIDAS] score of ≥11.
Reference
Tepper SJ, et al. Characterization of Dizziness Treatment-Emergent Adverse Events After Lasmiditan: Findings of the SAMURAI and SPARTAN Phase 3 Acute Migraine Treatment Trials . 60th Annual Scientific Meeting of the American Headache Society : abstr. PS38, 28 Jun 2018. Available from: URL: https://americanheadachesociety.org/events/60th-annual-scientific-meeting/
Rights and permissions
About this article
Cite this article
Dizziness is a dose-related AE following lasmiditan for migraine. Reactions Weekly 1714, 7 (2018). https://doi.org/10.1007/s40278-018-50187-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-50187-2